Previous 10 | Next 10 |
The following slide deck was published by Five Prime Therapeutics, Inc. in conjunction with this event. For further details see: Five Prime Therapeutics (FPRX) Presents at ASCO Gastrointestinal Cancer Symposium 2021 - Slideshow
Charah Solutions (CHRA) +105% on being awarded large-scale, 12-Year ash marketing contract.DBV Technologies (DBVT) +57% on FDA response regarding Viaskin Peanut application.ObsEva (OBSV) +43%.Atlantic Power (AT) +41% on being acquired by I Squared Capital.Senseonics Holdings (S...
Five Prime Therapeutics (FPRX) gains 25% in premarket in response to results from a Phase 2 FIGHT trial, evaluating bemarituzumab in advanced gastric or gastroesophageal junction ((GEJ)) cancer. Results will be presented at the 2021 ASCO Gastrointestinal Cancers Virtual Annual Sympo...
All three efficacy endpoints (PFS, OS and ORR) in the FIGHT Phase 2 trial met pre-specified statistical significance 2021 priorities for the bemarituzumab program include collaborating with regulatory agencies on next steps, initiating a global Phase 3 trial in gastric and GEJ can...
2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...
The seasonally-strongest baskets include gold and technology. The top stocks in each major sector right now. The best sectors include consumer goods, industrial goods, and financials. For further details see: The Top Stocks To Buy In The New Year
What the January effect means for small cap stocks. The strongest small-cap sectors and industries. The top small-cap stocks to buy now. For further details see: The Best Small-Cap Stocks To Buy Because Of The January Effect
Overview of Five Prime Therapeutics. Focus on the large molecule (biologic) Bemarituzumab, including existing patient need, recent clinical trial results, patent situation and possible competition. Model presented to help estimate potential worldwide sales of Bemarituzumab using R...
Detailed results of the Phase 2 FIGHT trial have been accepted for late breaker presentation during the Esophageal and Gastric cancer oral abstract session on January 15, 2021 Company to host webcast and conference call on January 15 at 1:30pm PST / 4:30pm EST Five Pri...
Shares of the clinical-stage cancer specialist Five Prime Therapeutics (NASDAQ: FPRX) gained a stately 312% over the course of November, according to data from S&P Global Market Intelligence . The drugmaker's shares blasted higher last month in response to positive mid-stage...
News, Short Squeeze, Breakout and More Instantly...
Five Prime Therapeutics Inc. Company Name:
FPRX Stock Symbol:
NASDAQ Market:
Five Prime Therapeutics Inc. Website:
Amgen Successfully Completes Acquisition Of Five Prime Therapeutics PR Newswire THOUSAND OAKS, Calif. , April 16, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced tender offer to purchase all out...
Amgen (NASDAQ: AMGN) recently announced plans to acquire Five Prime Therapeutics (NASDAQ: FPRX) for approximately $1.9 billion. The deal gives Amgen rights to bemarituzumab, which has made it through phase 2 testing. In this video from Motley Fool Live , recorded on ...
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) announced today that it has canceled its fourth quarter and full year 2020 earnings conference call, which was previously scheduled for Wednesday, March 10, 2021 at 1:30 p.m. PT / 4:30 p.m. ET. The cancellation is the result of the co...